Balakumar Swaminathan
Overview
Explore the profile of Balakumar Swaminathan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
1070
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Agostini H, Abreu F, Baumal C, Chang D, Csaky K, Demetriades A, et al.
Graefes Arch Clin Exp Ophthalmol
. 2024 Jun;
262(11):3437-3451.
PMID: 38847896
Intravitreal anti-vascular endothelial growth factor (VEGF) therapy is the standard of care for diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD); however, vision gains and anatomical improvements are...
2.
Khanani A, Kotecha A, Chang A, Chen S, Chen Y, Guymer R, et al.
Ophthalmology
. 2024 Feb;
131(8):914-926.
PMID: 38382813
Purpose: To evaluate 2-year efficacy, durability, and safety of the bispecific antibody faricimab, which inhibits both angiopoietin-2 and VEGF-A. Design: TENAYA (ClinicalTrials.gov identifier, NCT03823287) and LUCERNE (ClinicalTrials.gov identifier, NCT03823300) were...
3.
Takahashi K, Cheung C, Iida T, Lai T, Ohji M, Yanagi Y, et al.
Graefes Arch Clin Exp Ophthalmol
. 2023 Jun;
261(11):3125-3137.
PMID: 37294433
Purpose: To evaluate 1-year efficacy, durability, and safety of faricimab among patients from Asian countries in the TENAYA/LUCERNE trials of neovascular age-related macular degeneration (nAMD). Methods: Treatment-naïve patients with nAMD...
4.
Yuan F, Bosch J, Eikelboom J, Dagenais G, Connolly S, Belanger J, et al.
Clin Trials
. 2023 Feb;
20(2):166-175.
PMID: 36734212
Introduction: In clinical trials, event adjudication is a process to review and confirm the accuracy of outcomes reported by site investigators. Despite efforts to automate the communication between a clinical-data-and-coordination...
5.
Khanani A, Guymer R, Basu K, Boston H, Heier J, Korobelnik J, et al.
Ophthalmol Sci
. 2022 Oct;
1(4):100076.
PMID: 36246941
Purpose: To describe the design and rationale of the phase 3 TENAYA (ClinicalTrials.gov identifier, NCT03823287) and LUCERNE (ClinicalTrials.gov identifier, NCT03823300) trials that aimed to assess efficacy, safety, and durability of...
6.
Heier J, Khanani A, Quezada Ruiz C, Basu K, Ferrone P, Brittain C, et al.
Lancet
. 2022 Jan;
399(10326):729-740.
PMID: 35085502
Background: Faricimab is a bispecific antibody that acts through dual inhibition of both angiopoietin-2 and vascular endothelial growth factor A. We report primary results of two phase 3 trials evaluating...
7.
Holekamp N, Wykoff C, Schmitz-Valckenberg S, Mones J, Souied E, Lin H, et al.
Ophthalmology
. 2020 Feb;
127(6):769-783.
PMID: 32081489
Purpose: To better characterize visual function decline and geographic atrophy (GA) progression secondary to age-related macular degeneration (AMD). Design: Proxima A (NCT02479386)/Proxima B (NCT02399072) were global, prospective, noninterventional, observational clinical...
8.
Ntaios G, Swaminathan B, Berkowitz S, Gagliardi R, Lang W, Siegler J, et al.
Stroke
. 2019 Aug;
50(9):2477-2485.
PMID: 31401971
Background and Purpose- The sources of emboli in patients with embolic stroke of undetermined source (ESUS) are multiple and may not respond uniformly to anticoagulation. In this exploratory subgroup analysis...
9.
Perera K, Swaminathan B, Veltkamp R, Arauz A, Ameriso S, Marti-Fabregas J, et al.
Eur Stroke J
. 2019 Apr;
3(2):110-116.
PMID: 31008343
Introduction: The sources of emboli in those with embolic stroke of undetermined source may differ in old and young. We assessed the frequency, features and potential embolic sources of younger...
10.
Siegler J, Swaminathan B, Giruparajah M, Bosch J, Perera K, Hart R, et al.
Eur Stroke J
. 2019 Apr;
1(2):130-138.
PMID: 31008275
Incomplete evaluation of stroke patients may result in an unclear diagnosis. Our objective was to determine if older stroke patients more often undergo incomplete diagnostic evaluations versus younger patients in...